Themes Virale vectoren

Advice on the decision by the European Commission on the GMO status of viral replicon particles

17.06.2024

CGM/240617-01

Advisory letters
Detection of replication competent virus formation during production and use of lenti- and gammaretroviral vectors

31.01.2023

CGM 2023-01

Research reports
Research project on detection methods for replication-competent lentiviral and retroviral vectors

31.01.2023

CGM/230131-01

Advisory letters
Generic downscaling of containment requirements for work with viral replicons derived from alphaviruses and flaviviruses

23.12.2022

CGM/221223-01

Advisory reports
Viral replicon systems and their biosafety aspects –Inventory and description of viral replicon systems and characteristics relevant for risk assessment

23.12.2022

CGM 2022-06

Research reports
Generic environmental risk assessment of gene therapies that use GM cells containing free lentiviral particles

07.05.2020

CGM/200507-01

Advisory reports
Generic environmental risk assessment of clinical trials with AAV vectors

11.02.2020

CGM/190905-01

Advisory reports
Generic advice on containment levels for replication-deficient adenoviral vector systems

16.03.2018

CGM/180316-01

Advisory reports
Research report Assessment of preclinical gene therapy studies worldwide

04.09.2015

CGM 2015-03

Research reports